RUNX3 downregulation in human lung adenocarcinoma is independent of p53, EGFR or KRAS status

Pathology and Oncology Research

Volumn 18, Issue 4, 2012, Pages 783-792

  Omar, Mohd Feroz Mohd ^a,b   Ito, Kosei ^c   Nga, Min En ^d   Soo, Ross ^a,d   Peh, Bee Keow ^a,d   Ismail, Tuty Muliana ^d,e   Thakkar, Bhavin ^a   Soong, Richie ^a,d   Ito, Yoshiaki ^a,b   Salto Tellez, Manuel ^a,e,f  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c NAGASAKI UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES   (Japan)

^d NATIONAL UNIVERSITY HOSPITAL   (Singapore)

^e NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^f QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

EGFR; KRAS; Lung adenocarcinoma; P53; Promoter hypermethylation; RUNX3

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; K RAS PROTEIN; PROTEIN P53; TRANSCRIPTION FACTOR RUNX3;

ARTICLE; CANCER DIAGNOSIS; CANCER SCREENING; CONTROLLED STUDY; DOWN REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; MUTATIONAL ANALYSIS; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN METHYLATION; TISSUE MICROARRAY;

ADENOCARCINOMA; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CORE BINDING FACTOR ALPHA 3 SUBUNIT; DNA METHYLATION; DNA MUTATIONAL ANALYSIS; DOWN-REGULATION; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MUTATION; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TISSUE ARRAY ANALYSIS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84868487326     PISSN: 12194956     EISSN: 15322807     Source Type: Journal    
DOI: 10.1007/s12253-011-9485-5     Document Type: Article

References (59)

1. Brambilla E, Travis WD, Colby TV, Corrin B, Shimosato Y (2001) The new World Health Organization classification of lung tumours. Eur Respir J 18(6):1059-1068
2. Mattson ME, Pollack ES, Cullen JW (1987) What are the odds that smoking will kill you? Am J Public Health 77(4):425-431
3. Hessel PA, Gamble JF, McDonald JC (2005) Asbestos, asbestosis, and lung cancer: a critical assessment of the epidemiological evidence. Thorax 60(5):433-436
4. Lubin JH, Boice JD Jr (1997) Lung cancer risk from residential radon: meta-analysis of eight epidemiologic studies. J Natl Cancer Inst 89(1):49-57
5. Zhu CQ, ShihW, Ling CH, Tsao MS (2006) Immunohistochemical markers of prognosis in non-small cell lung cancer: a review and proposal for a multiphase approach to marker evaluation. J Clin Pathol 59(8):790-800
6. Belinsky SA, Nikula KJ, Palmisano WA, Michels R, Saccomanno G, Gabrielson E et al (1998) Aberrant methylation of p16INK4a is an early event in lung cancer and a potential biomarker for early diagnosis. Proc Natl Acad Sci 95(20):11891-11896
7. Bouchardy C, Benhamou S, Dayer P (1996) The effect of tobacco on lung cancer risk depends on CYP2D6 activity. Cancer Res 56 (2):251-253
8. El-Zein RA, Schabath MB, Etzel CJ, Lopez MS, Franklin JD, Spitz MR (2006) Cytokinesis-blocked micronucleus assay as a novel biomarker for lung cancer risk. Cancer Res 66(12):6449-6456
9. Marchand LL, Sivaraman L, Pierce L, Seifried A, Lum A, Wilkens LR et al (1998) Associations of CYP1A1, GSTM1, and CYP2E1 polymorphisms with lung cancer suggest cell type specificities to tobacco carcinogens. Cancer Res 58(21):4858-4863
10. SchwartzAG, PrysakGM, Bock CH, CoteML (2007) The molecular epidemiology of lung cancer. Carcinogenesis 28(3):507-518
11. Sellers TA, Potter JD, Bailey-Wilson JE, Rich SS, Rothschild H, Elston RC (1992) Lung Cancer Detection and Prevention: Evidence for an Interaction between Smoking and Genetic Predisposition. Cancer Res. 52(9-Supplement):2694s-7
12. Shaw GL, Falk RT, Frame JN, Weiffenbach B, Nesbitt JC, Pass HI et al (1998) Genetic polymorphism of CYP2D6 and lung cancer risk. Cancer Epidemiol Biomarkers Prev 7(3):215-219
13. Wistuba II, Mao L, Gazdar AF (2002) Smoking molecular damage in bronchial epithelium. Oncogene 21(48):7298-7306
14. Yamabuki T, Takano A, Hayama S, Ishikawa N, Kato T, Miyamoto M et al (2007) Dikkopf-1 as a novel serologic and prognostic biomarker for lung and esophageal carcinomas. Cancer Res 67 (6):2517-2525
15. Arenberg D (2004) In search of the holy grail: lung cancer biomarkers. Chest 126(2):325-326
16. Altshuler D, Daly MJ, Lander ES (2008) Genetic mapping in human disease. Science 322(5903):881-888
17. Duffy MJ, Crown J (2008) A personalized approach to cancer treatment: how biomarkers can help. Clin Chem 54(11):1770-1779
18. Brambilla C, Fievet F, Jeanmart M, de Fraipont F, Lantuejoul S, Frappat V et al (2003) Early detection of lung cancer: role of biomarkers. Eur Respir J. 21(39 suppl):36S-44
19. Bangsow C, Rubins N, Glusman G, Bernstein Y, Negreanu V, Goldenberg D et al (2001) The RUNX3 gene-sequence, structure and regulated expression. Gene 279(2):221-232
20. Ito Y (2008) RUNX genes in development and cancer: regulation of viral gene expression and the discovery of RUNX family genes. Adv Cancer Res 99:33-76
21. Hanai J-i, Chen LF, Kanno T, Ohtani-Fujita N, Kim WY, Guo W-H et al (1999) Interaction and Functional Cooperation of PEBP2/CBF with Smads. Synergistic induction of the immunoglobulin germline Cá promoter. J Biol Chem 274(44):31577-31582
22. Ito K, Lim AC-B, Salto-Tellez M, Motoda L, Osato M, Chuang LSH et al (2008) RUNX3 attenuates β-Catenin/T cell factors in intestinal tumorigenesis. Cancer Cell 14(3):226-237
23. Licchesi JDF, Westra WH, Hooker CM, Machida EO, Baylin SB, Herman JG (2008) Epigenetic alteration ofWnt pathway antagonists in progressive glandular neoplasia of the lung. Carcinogenesis 29 (5):895-904
24. Homma N, Tamura G, Honda T, Matsumoto Y, Nishizuka S, Kawata S et al (2006) Spreading of methylation within RUNX3 CpG island in gastric cancer. Cancer Sci 97(1):51-56
25. Lee JM, Kwon HJ, Bae SC, Jung HS (2010) Lung tissue regeneration after induced injury in Runx3 KO mice. Cell Tissue Res 341(3):465-470
26. Lee KS, Lee YS, Lee JM, Ito K, Cinghu S, Kim JH et al (2010) Runx3 is required for the differentiation of lung epithelial cells and suppression of lung cancer. Oncogene 29(23):3349-3361
27. Lau QC, Raja E, Salto-Tellez M, Liu Q, Ito K, Inoue Met al (2006) RUNX3 is frequently inactivated by dual mechanisms of protein mislocalization and promoter hypermethylation in breast cancer. Cancer Res 66(13):6512-6520
28. Subramaniam MM, Chan JY, Soong R, Ito K, Ito Y, Yeoh KG et al (2008) RUNX3 inactivation by frequent promoter hypermethylation and protein mislocalization constitute an early event in breast cancer progression. Breast Cancer Res Treat
29. Ito K, Liu Q, Salto-Tellez M, Yano T, Tada K, Ida H et al (2005) RUNX3, a novel tumor suppressor, is frequently inactivated in gastric cancer by protein mislocalization. Cancer Res 65(17):7743-7750
30. Ku J-L, Kang S-B, Shin Y-K, Kang HC, Hong S-H, Kim I-J et al (2004) Promoter hypermethylation downregulates RUNX3 gene expression in colorectal cancer cell lines. Oncogene 23(40):6736-6742
31. Li QL, Ito K, Sakakura C, Fukamachi H, Inoue K, Chi XZ et al (2002) Causal relationship between the loss of RUNX3 expression and gastric cancer. Cell 109(1):113-124
32. Salto-Tellez M, Peh BK, Ito K, Tan SH, Chong PY, Han HC et al (2006) RUNX3 protein is overexpressed in human basal cell carcinomas. Oncogene 25(58):7646-7649
33. Kim TY, Lee HJ, Hwang KS, Lee M, Kim JW, Bang YJ et al (2004) Methylation of RUNX3 in various types of human cancers and premalignant stages of gastric carcinoma. Lab Invest 84 (4):479-484
34. Yanada M, Yaoi T, Shimada J, Sakakura C, Nishimura M, Ito K et al (2005) Frequent hemizygous deletion at 1p36 and hypermethylation downregulate RUNX3 expression in human lung cancer cell lines. Oncol Rep 14(4):817-822
35. Lane D (2004) p53 from pathway to therapy. Carcinogenesis 25 (7):1077-1081
36. Cheng Y-L, Lee S-C, Harn H-J, Chen C-J, Chang Y-C, Chen J-C et al (2003) Prognostic prediction of the immunohistochemical expression of p53 and p16 in resected non-small cell lung cancer. Eur J Cardiothorac Surg 23(2):221-228
37. Maniwa Y, Yoshimura M, Obayashi C, Inaba M, Kiyooka K, Kanki M et al (2001) Association of p53 gene mutation and telomerase activity in resectable non-small cell lung cancer*. Chest 120(2):589-594
38. Piyathilake CJ, Frost AR, Manne U, Weiss H, Heimburger DC, Grizzle WE (2003) Nuclear accumulation of p53 is a potential marker for the development of squamous cell lung cancer in smokers*. Chest 123(1):181-186
39. Ettinger DS (2006) Clinical implications of EGFR expression in the development and progression of solid tumors: focus on nonsmall cell lung cancer. Oncologist 11(4):358-373
40. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW et al (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350(21):2129-2139
41. Jang TW, Oak CH, Chang HK, Suo SJ, Jung MH (2009) EGFR and KRAS mutations in patients with adenocarcinoma of the lung. Korean J Intern Med 24(1):48-54
42. Shigematsu H, Lin L, Takahashi T, Nomura M, Suzuki M,Wistuba II et al (2005) Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 97(5):339-346
43. Schmid K, Oehl N, Wrba F, Pirker R, Pirker C, Filipits M (2009) EGFR/KRAS/BRAF mutations in primary lung adenocarcinomas and corresponding locoregional lymph node metastases. Clin Cancer Res 15(14):4554-4560
44. Eberhard DA, Johnson BE, Amler LC, Goddard AD, Heldens SL, Herbst RS et al (2005) Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 23 (25):5900-5909
45. Tsunematsu T, Kudo Y, Iizuka S, Ogawa I, Fujita T, Kurihara H et al (2009) RUNX3 has an oncogenic role in head and neck cancer. PLoS One 4(6):e5892
46. Yanagawa N, Tamura G, Oizumi H, Endoh M, Sadahiro M, Motoyama T (2011) Inverse correlation between EGFR mutation and FHIT, RASSF1A and RUNX3 methylation in lung adenocarcinoma: relation with smoking status. Anticancer Res 31(4):1211-1214
47. Das K, Mohd Omar MF, Ong CW, Bin Abdul Rashid S, Peh BK, Putti TC et al (2008) TRARESA: a tissue microarray-based hospital systemfor biomarker validation and discovery. Pathology 40 (5):441-449
48. Yano T, Ito K, Fukamachi H, Chi X-Z, Wee H-J, Inoue K-i et al (2006) The RUNX3 tumor suppressor upregulates bim in gastric epithelial cells undergoing transforming growth factor â-induced apoptosis. Mol Cell Biol 26(12):4474-4488
49. Soong R, Robbins PD, Dix BR, Grieu F, Lim B, Knowles S et al (1996) Concordance between p53 protein overexpression and gene mutation in a large series of common human carcinomas. Hum Pathol 27(10):1050-1055
50. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB (1996) Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 93 (18):9821-9826
51. Krypuy M, Newnham G, Thomas D, Conron M, Dobrovic A (2006) High resolution melting analysis for the rapid and sensitive detection of mutations in clinical samples: KRAS codon 12 and 13 mutations in non-small cell lung cancer. BMC Cancer 6(1):295
52. Chin TM, Anuar D, Soo R, Salto-Tellez M, Li WQ, Ahmad B et al (2007) Detection of epidermal growth factor receptor variations by partially denaturing HPLC. Clin Chem 53(1):62-70
53. Araki K, Osaki M, Nagahama Y, Hiramatsu T, Nakamura H, Ohgi S et al (2005) Expression of RUNX3 protein in human lung adenocarcinoma: implications for tumor progression and prognosis. Cancer Sci 96(4):227-231
54. Ito K, Inoue Ki, Bae SC, Ito Y (2009) Runx3 expression in gastrointestinal tract epithelium: resolving the controversy. Oncogene 28(10):1379-1384
55. Li QL, Kim HR, Kim WJ, Choi JK, Lee YH, Kim HM et al (2004) Transcriptional silencing of the RUNX3 gene by CpG hypermethylation is associated with lung cancer. Biochem Biophys Res Commun 314(1):223-228
56. Sato K, Tomizawa Y, Iijima H, Saito R, Ishizuka T, Nakajima T et al (2006) Epigenetic inactivation of the RUNX3 gene in lung cancer. Oncol Rep 15(1):129-135
57. Yanagawa N, Tamura G, Oizumi H, Takahashi N, Shimazaki Y, Motoyama T (2003) Promoter hypermethylation of tumor suppressor and tumor-related genes in non-small cell lung cancers. Cancer Sci 94 (7):589-592
58. Ibrahim AEK, Arends MJ, Silva A-L, Wyllie AH, Greger L, Ito Y et al (2010) Sequential DNA methylation changes are associated with DNMT3B overexpression in colorectal neoplastic progression. Gut
59. Soung YH, Lee JW, Kim SY, Seo SH, Park WS, Nam SW et al (2005) Mutational analysis of EGFR and K-RAS genes in lung adenocarcinomas. Virchows Arch 446(5):483-488